Null-type SH2B3 mutations are potential drivers in a subset of Ph-negative myeloproliferative neoplasms

Affiliations

¹ Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Pathology, Geisinger Medical Center, Danville, Pennsylvania, USA.
³ ARUP Laboratories, Salt Lake City, Utah, USA.
⁴ Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
⁵ Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
⁶ Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Free article

Xi Zhang et al. Am J Hematol. 2024 Sep.

Free article

. 2024 Sep;99(9):1841-1844.

doi: 10.1002/ajh.27411. Epub 2024 Jun 25.

¹ Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Pathology, Geisinger Medical Center, Danville, Pennsylvania, USA.
³ ARUP Laboratories, Salt Lake City, Utah, USA.
⁴ Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
⁵ Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
⁶ Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

No abstract available

References

1. Baran‐Marszak F, Magdoud H, Desterke C, et al. Expression level and differential JAK2‐V617F‐binding of the adaptor protein Lnk regulates JAK2‐mediated signals in myeloproliferative neoplasms. Blood. 2010;116:5961‐5971.
1. Gery S, Cao Q, Gueller S, Xing H, Tefferi A, Koeffler HP. Lnk inhibits myeloproliferative disorder‐associated JAK2 mutant, JAK2V617F. J Leukoc Biol. 2009;85:957‐965.
1. Camps C, Petousi N, Bento C, et al. Gene panel sequencing improves the diagnostic work‐up of patients with idiopathic erythrocytosis and identifies new mutations. Haematologica. 2016;101:1306‐1318.
1. Chen Y, Fang F, Hu Y, et al. The polymorphisms in LNK gene correlated to the clinical type of myeloproliferative neoplasms. PLoS One. 2016;11:e0154183.
1. Coltro G, Lasho TL, Finke CM, et al. Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Am J Hematol. 2019;94:E231‐E234.